Vanguard Group Inc Chemo Centryx, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $4.75 Million - $11.1 Million	214,367 Added 3.69%	6,020,594 $311 Million
Q2 2022 Aug 12, 2022	BUY	$15.36 - $27.51 $10.6 Million - $18.9 Million	686,912 Added 13.42%	5,806,227 $144 Million
Q1 2022 May 13, 2022	BUY	$22.22 - $39.12 $451,843 - $795,505	20,335 Added 0.4%	5,119,315 $128 Million
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $4.7 Million - $10.4 Million	255,927 Added 5.28%	5,098,980 $186 Million
Q3 2021 Nov 12, 2021	SELL	$13.18 - $19.83 $219,460 - $330,189	-16,651 Reduced 0.34%	4,843,053 $82.8 Million
Q2 2021 Aug 13, 2021	BUY	$9.59 - $50.88 $46.6 Million - $247 Million	4,859,704 New	4,859,704 $65.1 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.